Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Treasury Shares (2023 - 2025)

Stoke Therapeutics has reported Treasury Shares over the past 3 years, most recently at $1.8 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 43.44% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $1.8 million, up 43.44%, while the annual FY2025 figure was $1.8 million, 43.44% up from the prior year.
  • Treasury Shares for Q4 2025 was $1.8 million at Stoke Therapeutics, up from $1.2 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $1.8 million in Q4 2025 and troughed at $1.2 million in Q4 2024.
  • A 3-year average of $1.5 million and a median of $1.5 million in 2023 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: dropped 19.18% in 2024 and later surged 43.44% in 2025.
  • Year by year, Treasury Shares stood at $1.5 million in 2023, then fell by 19.18% to $1.2 million in 2024, then surged by 43.44% to $1.8 million in 2025.
  • Business Quant data shows Treasury Shares for STOK at $1.8 million in Q4 2025, $1.2 million in Q4 2024, and $1.5 million in Q4 2023.